Effect of pleural infusion of recombinant human endostatin in patients with ma-lignant pleural effusion in non-small cell lung cancer
Objective To analyze the effects of different doses of recombinant human endostatin(Endostar)on the efficacy and safety in patients with non-small cell lung cancer(NSCLC)with malignant pleural effusion.Methods 150 patients with malignant pleural effusion of NSCLC were selected as subjects.All patients received Endostar thoracic perfusion therapy and were divided into 3 groups according to different doses:low-dose group(n=50,30 mg Endostar),medium-dose group(n=50,60 mg Endostar),high-dose group(n=50,90 mg Endostar).The efficacy,tumor biomarker changes[cytokeratin fragment 21-1(CYFRA21-1),carcinoembryonic antigen(CEA),cancer antigen 125(CA125),and cancer antigen 19-9(CA19-9)],and safety were compared among 3 groups.Results After treatment,the total effective rate of medium-dose group and high-dose group was higher than that of low-dose group(P＜0.05),but there was no difference between medium-dose group and high-dose group(P＞0.05).The indexes of CYFRA21-1,CEA,CA125 and CA19-9 in 3 groups were decreased(P＜0.05),and the indexes of CEA,CA125 and CA19-9 in low-dose group were higher than those in medium-dose and high-dose groups(P＜0.05).There was no significant difference in the total incidence of complications among the 3 groups(P＞0.05).Conclusion Pleural perfusion of 60 mg and 90 mg Endostar can improve the efficacy of NSCLC patients with malignant pleural effusion,and help to actively control the level of tumor markers,and the drug risk does not increase with the increase of Endostar dose.
recombinant human endostatin(Endostar)pleural perfusionnon-small cell lung cancermalignant pleural effusion
NETL
NSTL
万方数据
